The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review

• Autor(a) principal: Johannes Bitzer
• Data de Publicação: 2017
• Outros Autores: Thomas Römer, Agnaldo Lopes da Silva Filho
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1080/13625187.2017.1317339; http://hdl.handle.net/1843/51673; https://orcid.org/0000-0002-8486-7861
• topic: Hyperandrogenism; Cyproterone acetate; Ethinylestradiol; Hirsutism; Acne; Seborrhea; Alopecia; Polycystic ovary syndrome; Hiperandrogenismo; Acetato de ciproterona; Etinilestradiol; Hirsutismo; Acne vulgar; Dermatite seborreica; Alopecia; Síndrome do ovário policístico

Introduction: Hyperandrogenism affects approximately 10–20% of women of reproductive age. Hyperandrogenic skin symptoms such as hirsutism, acne, seborrhea and alopecia are associated with significant quality of life and psychological impairment. Women with abnormalities in androgen metabolism may have accompanying anovulation and/or polycystic ovary syndrome (PCOS), both of which have reproductive and metabolic implications if left untreated. Cyproterone acetate (CPA), combined with ethinylestradiol (EE), is indicated for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age. Objective: To review the data on the efficacy and safety of CPA 2 mg/EE 35 lg for the treatment of hyperandrogenic skin symptoms in women. Methods: A non-systematic narrative review based on a literature search of the PubMed database. Results: Seventy eight studies were identified. The majority of sufficiently powered studies show a high efficacy of CPA 2mg/EE 35 lg in the treatment of severe acne and hirsutism. Studies show that therapeutic response in women with hirsutism requires a long-term approach and that hyperandrogenic skin symptoms in patients with PCOS are efficiently treated. Additional benefits include cycle control and, in some women, improvement in mood and perception of body image. Safety and tolerability data are summarized by the pharmacovigilance risk assessment committee (PRAC) of the European Medicine’s Agency’s (EMA). Conclusions: This review provides a comprehensive overview about the efficacy of CPA 2mg/EE 35 lg in the treatment of hyperandrogenic skin symptoms, thus allowing both health care professionals and women to balance the risks and benefits of treatment based on evidence.